Search research articles
Contact Us
Filters
Showing results (31-40 of 52) with videos related to
Page
of 6
Sort By:
Molecular Therapy. Oncology
|
April 10, 2024
Mediation of antitumor activity by AZD4820 oncolytic vaccinia virus encoding IL-12
Cheyne Kurokawa, Sonia Agrawal, Abhisek Mitra, et al.
Nature Medicine
|
September 30, 2021
Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection
Shuo Feng, Daniel J Phillips, Thomas White, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
November 21, 2022
AZD7442 (Tixagevimab/Cilgavimab) for Post-Exposure Prophylaxis of Symptomatic Coronavirus Disease 2019
Myron J Levin, Andrew Ustianowski, Steven Thomas, et al.
Ebiomedicine
|
October 13, 2022
Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial
Meera Madhavan, Adam J Ritchie, Jeremy Aboagye, et al.
The Lancet. Microbe
|
October 2, 2023
Immunogenicity and safety of AZD2816, a beta (B.1.351) variant COVID-19 vaccine, and AZD1222 (ChAdOx1 nCoV-19) as third-dose boosters for previously vaccinated adults: a multicentre, randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study in the UK and Poland
Maheshi N Ramasamy, Elizabeth J Kelly, Seth Seegobin, et al.
Nature Communications
|
April 8, 2024
Author Correction: Molecular and phenotypic characteristics of RSV infections in infants during two nirsevimab randomized clinical trials
Bahar Ahani, Kevin M Tuffy, Anastasia A Aksyuk, et al.
Nature Communications
|
July 19, 2023
Molecular and phenotypic characteristics of RSV infections in infants during two nirsevimab randomized clinical trials
Bahar Ahani, Kevin M Tuffy, Anastasia A Aksyuk, et al.
The Journal of Clinical Investigation
|
September 15, 2022
Durability of protection and immunogenicity of AZD1222 (ChAdOx1 nCoV-19) COVID-19 vaccine over 6 months
Magdalena E Sobieszczyk, Jill Maaske, Ann R Falsey, et al.
The New England Journal of Medicine
|
April 20, 2022
Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19
Myron J Levin, Andrew Ustianowski, Stéphane De Wit, et al.
The Lancet. Microbe
|
June 15, 2024
Immunogenicity and safety of beta variant COVID-19 vaccine AZD2816 and AZD1222 (ChAdOx1 nCoV-19) as primary-series vaccination for previously unvaccinated adults in Brazil, South Africa, Poland, and the UK: a randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study
Sue Ann Costa Clemens, Brett Jepson, Qasim E Bhorat, et al.
Page
of 6
Search research articles
Search
Showing results (31-40 of 52) with videos related to
Sort By:
Page
of 6
Molecular Therapy. Oncology
|
April 10, 2024
Mediation of antitumor activity by AZD4820 oncolytic vaccinia virus encoding IL-12
Cheyne Kurokawa, Sonia Agrawal, Abhisek Mitra, et al.
Nature Medicine
|
September 30, 2021
Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection
Shuo Feng, Daniel J Phillips, Thomas White, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
November 21, 2022
AZD7442 (Tixagevimab/Cilgavimab) for Post-Exposure Prophylaxis of Symptomatic Coronavirus Disease 2019
Myron J Levin, Andrew Ustianowski, Steven Thomas, et al.
Ebiomedicine
|
October 13, 2022
Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial
Meera Madhavan, Adam J Ritchie, Jeremy Aboagye, et al.
The Lancet. Microbe
|
October 2, 2023
Immunogenicity and safety of AZD2816, a beta (B.1.351) variant COVID-19 vaccine, and AZD1222 (ChAdOx1 nCoV-19) as third-dose boosters for previously vaccinated adults: a multicentre, randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study in the UK and Poland
Maheshi N Ramasamy, Elizabeth J Kelly, Seth Seegobin, et al.
Nature Communications
|
April 8, 2024
Author Correction: Molecular and phenotypic characteristics of RSV infections in infants during two nirsevimab randomized clinical trials
Bahar Ahani, Kevin M Tuffy, Anastasia A Aksyuk, et al.
Nature Communications
|
July 19, 2023
Molecular and phenotypic characteristics of RSV infections in infants during two nirsevimab randomized clinical trials
Bahar Ahani, Kevin M Tuffy, Anastasia A Aksyuk, et al.
The Journal of Clinical Investigation
|
September 15, 2022
Durability of protection and immunogenicity of AZD1222 (ChAdOx1 nCoV-19) COVID-19 vaccine over 6 months
Magdalena E Sobieszczyk, Jill Maaske, Ann R Falsey, et al.
The New England Journal of Medicine
|
April 20, 2022
Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19
Myron J Levin, Andrew Ustianowski, Stéphane De Wit, et al.
The Lancet. Microbe
|
June 15, 2024
Immunogenicity and safety of beta variant COVID-19 vaccine AZD2816 and AZD1222 (ChAdOx1 nCoV-19) as primary-series vaccination for previously unvaccinated adults in Brazil, South Africa, Poland, and the UK: a randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study
Sue Ann Costa Clemens, Brett Jepson, Qasim E Bhorat, et al.
Page
of 6